Tandem laser-induced fluorescence and mass spectrometry detection for high-performance liquid chromatography analysis of the in vitro metabolism of doxorubicin.
Structural characterization, identification, and quantification of xenobiotics and their metabolic products commonly require the use of at least two different techniques. This has been the case in the analysis of metabolic products of doxorubicin, a widely used fluorescent anthracycline for the treatment of tumors and leukemia. In this work, we combine high-performance liquid chromatography (HPLC) with a tandem laser-induced fluorescence (LIF) and mass spectrometry (MS) detection scheme for the characterization of doxorubicin and its metabolites produced in the postmitochondrial fraction prepared from Fischer 344 rat liver. LIF detection allowed quantification of the metabolic compounds while MS detection aided in the identification of the metabolites. Using this HPLC-LIF-MS methodology, the disappearance of doxorubicin and the appearance of 7-deoxydoxorubicinone and 7-deoxydoxorubicinolone were monitored over the course of 40 min. This application demonstrates the potential of the tandem LIF-MS detection scheme in quantification and characterization of biotransformations of fluorescent xenobiotics of biomedical and environmental relevance. Furthermore, this detection scheme would be particularly relevant in the analysis of fluorescent analytes in complex samples and in validation of methods for the analysis of such samples that typically rely only on LIF detectors.
Katzenmeyer
Joseph B
JB
Department of Chemistry, University of Minnesota, Minneapolis, Minnesota 55455, USA.
Eddy
Christopher V
CV
Arriaga
Edgar A
EA
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000032:analysis* / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000032:analysis* / Q000378:metabolism; D005456:Fluorescent Dyes / Q000737:chemistry; D007834:Lasers; D008099:Liver / Q000737:chemistry; D013058:Mass Spectrometry / Q000379:methods*; D009279:Naphthacenes / Q000032:analysis; D051381:Rats
D000903:Antibiotics, Antineoplastic; D005456:Fluorescent Dyes; D009279:Naphthacenes; C074869:7-deoxy-13-dihydroadriamycinone; D004317:Doxorubicin; C049326:7-deoxyadriamycin aglycone
Xenobiotica. 2005 Dec;35(12):1121-33
16418065
Chem Res Toxicol. 2000 Dec;13(12):1336-41
11123976
Anal Chem. 2003 Jan 1;75(1):8-15
12530812
J Clin Oncol. 1988 Mar;6(3):517-26
3162516
Chem Res Toxicol. 2000 May;13(5):414-20
10813659
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Mar 15;877(8-9):837-41
19246257
Talanta. 2008 Jan 15;74(4):887-95
18371724
Drug Metab Dispos. 1976 Jan-Feb;4(1):79-87
3405
Exp Gerontol. 1989;24(2):159-71
2721604
Clin Pharmacol Ther. 2008 Jun;83(6):898-903
18388866
Anal Chem. 2008 May 15;80(10):3838-45
18426228
Drug Metab Dispos. 1980 May-Jun;8(3):152-6
6104578
Arch Biochem Biophys. 1991 Feb 1;284(2):292-7
1846520
J Chromatogr B Biomed Sci Appl. 2000 Feb 11;738(2):281-91
10718646
J Pharmacol Exp Ther. 1975 Oct;195(1):41-9
1181403
Chem Biol Interact. 1999 Aug 30;122(1):27-39
10475613
Anal Chem. 2005 Mar 15;77(6):1672-83
15762571
Gerontology. 1982;28 Suppl 1:101-12
7044902
Biomed Chromatogr. 2002 Aug;16(5):311-8
12210504
Oncogene. 1999 Nov 18;18(48):6641-6
10597269
Int J Biochem. 1994 Dec;26(12):1341-50
7890113
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 5;808(2):295-302
15261824
Pharmacol Rev. 2004 Jun;56(2):185-229
15169927
Electrophoresis. 2005 Apr;26(7-8):1389-97
15765475